Department of Ophthalmology, Chongqing General Hospital, Chongqing, China.
Department of Pharmacy, Chongqing General Hospital, Chongqing, China.
Clinics (Sao Paulo). 2020 Nov 30;75:e1874. doi: 10.6061/clinics/2020/e1874. eCollection 2020.
Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for lowering IOP. This study compared the safety and efficacy of latanoprost, latanoprostene bunod, and timolol maleate in patients with open-angle glaucoma.
Patients who received latanoprost eye drops once daily in the evening were included in the latanoprost Ophthalmic Solutions (LP) cohort (n=104). Those who received latanoprostene bunod eye drops once daily in the evening were included in the Latanoprostene Bunod (LB) cohort (n=94). Those who received timolol eye drops twice daily were included in the Timolol Maleate (TM) cohort (n=115). All treatments were administered to the affected eye(s) for 3 months. Informed Consent has been taken from each participant before the trial.
At the end of 3 months of treatment, latanoprost, latanoprostene bunod, and timolol were all successful in reducing IOP. The LB cohort had the highest reduction in IOP, compared to the LP and TM cohorts. All treatments had some common adverse ocular effects.
Latanoprostene bunod was superior to latanoprost and timolol for the treatment of open-angle glaucoma.
马来酸噻吗洛尔已被报道为一种比拉坦前列素更安全的眼压（IOP）降低治疗方法。美国食品和药物管理局批准了拉坦前列素氮氧化物供体前药拉坦前列素烯丙基，用于降低 IOP。本研究比较了拉坦前列素、拉坦前列素烯丙基和马来酸噻吗洛尔在开角型青光眼患者中的安全性和疗效。
接受拉坦前列素滴眼液每晚一次治疗的患者纳入拉坦前列素眼用溶液（LP）队列（n=104）。接受拉坦前列素烯丙基滴眼液每晚一次治疗的患者纳入拉坦前列素烯丙基（LB）队列（n=94）。接受马来酸噻吗洛尔滴眼液每天两次治疗的患者纳入马来酸噻吗洛尔（TM）队列（n=115）。所有治疗均在 3 个月内用于受影响的眼睛。在试验前，已从每位参与者处获得知情同意。
在 3 个月的治疗结束时，拉坦前列素、拉坦前列素烯丙基和马来酸噻吗洛尔均成功降低了 IOP。与 LP 和 TM 队列相比，LB 队列的 IOP 降低幅度最大。所有治疗均有一些常见的眼部不良反应。
拉坦前列素烯丙基在治疗开角型青光眼方面优于拉坦前列素和马来酸噻吗洛尔。
